stockrow
Friday 6 November 2026
Export ADPT’s income statement to Excel — free account
Adaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
26.83
0.00
0.00%
Follow ADPT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 6 | 5 | 6 |
| (27.84%) | (23.97%) | (38.68%) | (36.34%) | ||
| (11.31%) | (9.77%) | (11.23%) | (12.02%) | ||
ROIC |
0.00% | (494.38%) | (16.57%) | 0.00% | |
Return on Tangible Assets |
(24.35%) | (21.09%) | (17.62%) | (21.92%) | |
Average Days of Receivables |
66.37 | 59.70 | 58.66 | 81.66 | |
Free Cash Flow per Share |
(0.32) | (0.19) | (0.15) | (0.05) | |
Free Cash Flow |
(48.94) | (29.53) | (24.03) | (8.82) | |
Capital Expenditures |
(2.96) | (2.50) | (3.02) | (4.54) | |
| Other line items | |||||
Cash ROIC |
(10.83%) | (6.67%) | (2.90%) | (1.83%) | |
Accounts Receivable Turnover |
6.01 | 6.43 | 6.57 | 5.35 | |
Accounts Payable Turnover |
10.39 | 9.15 | 12.39 | 9.17 | |
Inventory Turnover |
7.82 | 7.35 | 7.96 | 7.71 | |
Average Days of Payables |
33.08 | 48.02 | 25.42 | 30.93 | |
Days of Inventory on Hand |
50.23 | 55.96 | 50.91 | 47.64 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
33.85% | 31.55% | 28.63% | 27.91% | |
Selling, General and Administrative Expense of Revenue |
60.39% | 58.95% | 58.55% | 61.85% | |
Share Based Compensation of Revenue |
18.59% | 17.35% | 15.91% | 15.49% | |
Interest Coverage |
(4.85) | (3.97) | (3.25) | (5.33) | |
Operating CF/Net income |
0.77 | 0.54 | 0.33 | 0.06 | |
Depreciation/Fixed assets |
0.45 | 0.50 | 0.51 | 0.00 | |
Capex/Depreciation |
(0.19) | (0.16) | (0.20) | 0.00 | |
Revenue per Share |
1.83 | 1.90 | 1.93 | 1.86 | |
Operating CF per Share |
(0.30) | (0.17) | (0.13) | (0.03) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | (0.03) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 |
Columns are period end dates · fundamentals updated 4 Nov 2026